financetom
Business
financetom
/
Business
/
Foran Mining Reported Q4 2024 Construction Progress at McIlvenna Bay
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Foran Mining Reported Q4 2024 Construction Progress at McIlvenna Bay
Feb 11, 2025 5:03 AM

07:37 AM EST, 02/11/2025 (MT Newswires) -- Foran Mining ( FMCXF ) , which rose 2% yesterday, on Tuesday said its 100% owned McIlvenna Bay project in Saskatchewan, Canada, "continues to advance steadily, with significant progress made across key areas of development".

"Entering the most important year in our company's history, we are building on a strong 2024 as we advance toward producer status. Significant strides in engineering, procurement, and development in the fourth quarter have positioned us for the next phase of execution -- led through our Integrated Project Management Team with G Mining Services and our strategy to self-perform," said Foran Chief Executive Dan Myerson. "McIlvenna Bay is more than just a mining project -- it's a generational opportunity to establish a premier producer in a world class jurisdiction, ensuring a secure, sustainable, and scalable supply of critical minerals for North America."

The company said the construction team in Q4, had started to erect structural steel for the plant. Foran said enclosure around the grinding mills is scheduled for completion by March 2025 with the balance of structural steel expected to be completed by the end of Q1 2025.

Foran Mining ( FMCXF ) expects engineering to be completed by the end of Q1 and to complete about 7,000m of decline development in 2025. The company added that underground crews were still on track to build a 272,000 tonne ore stockpile prior to mill production ramp-up.

The project remains on schedule to start hot commissioning in the second half of 2025 and commercial production in the first half of 2026.

Shares closed up $0.080 or 2%, at $4.010 on Monday on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MOVES-Goldman Sachs' Spain and Portugal co-head Alvaro del Castano to retire after 30 years
MOVES-Goldman Sachs' Spain and Portugal co-head Alvaro del Castano to retire after 30 years
Oct 8, 2025
Oct 8 (Reuters) - Goldman Sachs Group ( GS ) said in an internal memo seen by Reuters that Alvaro del Castano, its co-head for Spain and Portugal and in charge of private wealth management in the region, will retire after more than three decades at the bank. He is leaving the bank after writing opinion pieces critical of U.S....
Metal coating services firm AZZ Q2 adjusted EBITDA misses estimates
Metal coating services firm AZZ Q2 adjusted EBITDA misses estimates
Oct 8, 2025
Overview * AZZ Inc ( AZZ ) fiscal Q2 sales rise 2% yr/yr to $417.3 mln * Adjusted EPS for fiscal Q2 of $1.55 * Adjusted EBITDA for fiscal Q2 misses analyst expectations Outlook * AZZ maintains FY2026 sales guidance at $1.625 - $1.725 bln * Company expects FY2026 adjusted EBITDA of $360 - $400 mln * AZZ projects FY2026...
Zenta Group Company Limited Announces Full Exercise of Over-Allotment Option
Zenta Group Company Limited Announces Full Exercise of Over-Allotment Option
Oct 8, 2025
MACAU, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Zenta Group Company Limited ( ZGM ) (“Zenta Group” or the “Company”), a Macau-based professional services provider that offers consultation services to industrial park, business investment and sales of fintech products and services, today announced that the underwriters of its previously announced initial public offering (the “Offering”) have exercised their over-allotment option (the...
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer
Oct 8, 2025
Oct 8 (Reuters) - The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals' ( REGN ) immunotherapy, Libtayo, as an add-on treatment for skin cancer patients at high risk of their disease returning after surgery and radiation, the drugmaker said. Libtayo is already approved in the U.S. for advanced skin cancer, basal cell carcinoma, advanced non-small cell lung...
Copyright 2023-2026 - www.financetom.com All Rights Reserved